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What’s already known about this topic?
 Vitiligo is a common skin condition with significant psychological impact.
 Topical corticosteroids (TCS) are standard care for vitiligo. Narrowband UVB (NB-
UVB) is only available in secondary care as full-body treatment.
 Economic evidence for hand-held NB-UVB in combination with topical 
corticosteroid (TCs) is absent.A
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What does this study add?
 Combination treatment, compared to TCS alone, has the lowest incremental cost 
per successful treatment. Whether this is considered cost-effective depends on 
decision makers’ judgement on how much they are willing to pay to achieve a 
successful treatment. 
 Generic utility instruments, such as the EQ-5D-5L, may not be appropriate for 
vitiligo studies due to high ceiling effects. Measurement of quality of life for this 
condition warrants further research. 
 This study provides results that can be compared with new emerging vitiligo 
treatments.
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Summary
Background: Economic evidence for vitiligo treatments is absent. 
Objective: To determine the cost-effectiveness of (a) hand-held narrowband-UVB (NB-
UVB) and (b) combination of topical corticosteroid (TCS) and NB-UVB compared to TCS 
for localised vitiligo.
Methods: Cost-effectiveness analysis alongside a pragmatic, 3-arm, placebo-controlled 
RCT with 9 months’ treatment. 517 Adults and children (aged ≥5 years) with active vitiligo 
affecting <10% of skin recruited from secondary care and community were randomised 
1:1:1 to receive: TCS; NB-UVB; or both. Cost per successful treatment (measured on the 
Vitiligo Noticeability Scale) was estimated. Secondary cost-utility analyses measured 
QALYs using the EQ-5D-5L for those aged 11+ and CHU-9D for those aged 5 to <18. 
Results: Mean (SD) cost per participant was £774.4 (83.71) for NB-UVB, £813.38 
(111.39) for combination treatment and £599.98 (96.18) for TCS. In analyses adjusted for 
age and target patch location, incremental difference in cost for combination treatment 
compared to TCS was £211.46 (95% CI 188.10 to 234.81), corresponding to a risk 
difference of 10.94% (Number-Needed-To-Treat (NNT= 9). Incremental cost was 
£1,932.35 per successful treatment.  The incremental difference in cost for NB-UVB 
compared to TCS was £173.44 (95% CI 150.55 to 196.32) with a risk difference of 5.20% 
(NNT=19). Incremental cost was £3,335.74 per successful treatment. 
Conclusion: Combination treatment, compared to TCS alone, has a lower incremental 
cost per additional successful treatment than NB-UVB only. Combination treatment would 
be considered cost effective if decision makers are willing to pay £1,932 per additional 
treatment success.
Trial registration: ISRCTN17160087. 8th Jan 2015
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Introduction
A 2018 systematic review showed that the economic evidence for vitiligo treatment is 
virtually non-existent1. One of two studies identified in this review estimated the annual 
direct cost of treating vitiligo in the USA to be $15,000,000 for the price year 20042. The 
other study demonstrated that 32.5% of people with vitiligo would be willing to make a 
one-off payment of €5000 for a cure (2006 price year)3, allowing an estimate of the 
maximum potential for benefit should a “cure” be found. Although these papers indicate 
the cost to an affected person and health care system, they  do not provide evidence to 
inform resource allocation decisions. No papers were identified that undertook full 
economic evaluations (those which compare costs and benefits of two or more 
interventions4) of vitiligo treatments alongside clinical trials or as economic modelling. 
This paper reports the first full economic evaluation of treatment for localised, non-
segmental vitiligo, including current standard treatment Topical Corticosteroids (TCS) and 
new treatment (home-based NB-UVB light therapy), alone and in combination with TCS, 
with the aim of estimating the cost effectiveness of these treatments for the UK NHS.
Methods
This health economic evaluation estimated the within-trial cost-effectiveness of
i) active hand-held NB-UVB light compared to TCS (standard care) and
ii) combination of active hand-held NB-UVB plus TCS compared to TCS (standard 
care)
in terms of cost per additional treatment success (henceforth referred to as treatment 
success) at the end of the treatment period (9 months) for the treatment of limited, non-
segmental vitiligo, using individual level data collected within the trial. A treatment period 
of 9 months was chosen to reflect clinical practice where clinical experience and clinical 
guidelines suggest that treatment should be initiated for a minimum of 3-4 months, but 
that treatment would normally be required for a longer period in order to achieve a 
clinically meaningful treatment response.A
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A secondary objective was to undertake cost utility analyses for those aged 11 and over 
using the EQ-5D-5L and separately for participants aged under 18 years using the CHU-
9D. Typically, a cost-utility analysis would form the primary analysis as it enables 
decision makers to compare the cost effectiveness of a range of interventions for different 
conditions on a common scale. As utility is measured differently in adults and children a 
common cost-utility analysis was not possible, so a clinical outcome was used. Also cost-
utility instruments are considered less effective at capturing the psychological impact on 
quality of life, which is considered to be more important than physical impacts in vitiligo. 
A-priori we were also sceptical that available generic utility instruments would capture the 
health-related quality of life aspects that people living with vitiligo experience. 
The evaluation was undertaken in line with published guidelines for the economic 
evaluation of health care interventions 4-8. A health economics analysis plan was written 
and approved before the trial database was locked. A full trial report will be available 
through the NIHR Journal series9 and the clinical results paper is available in this 
journal10.
The trial was conducted in the UK National Health Service (the NHS) - a publicly-funded 
healthcare that is largely free of charge at the point of use. Therefore, the analysis was 
primarily from an NHS perspective, in keeping with the NICE reference case8. In a 
sensitivity analysis, out of pocket costs incurred by participants (or parents/guardians) are 
presented reflecting a personal perspective. 
Resources use and costs
The primary analysis captured the intervention costs (including any side-effect costs) to 
the NHS and the participant’s wider use of the NHS (including primary care visits; 
secondary care outpatient, inpatient and A&E visits; and prescriptions) as a result of 
vitiligo. Participants’ personal out of pocket expenses (for example, camouflage/ makeup, 
sun cream and sun care) incurred from vitiligo were also captured in a separate 
sensitivity analysis taking a broader perspective. Participant time burden for home 
treatment was not costed, but is reported elsewhere 9, 10. 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved
Resource use for the intervention phase was collected at 3, 6, and 9 months using 
information recorded by participants in daily diaries and collated by the researcher at 
follow-up visits. Intervention and side effect related resource use was recorded in Clinical 
Reports Forms. Further questionnaires collected resource use data at 12, 15, 18 and 21 
months for the follow-up phase. 
Intervention cost was estimated at the individual level. Participants randomised to NB-
UVB alone were also given a placebo ointment whilst those in the TCS alone group 
received a dummy NB-UVB device. The dummy devices and placebo ointment were not 
costed. 
NB-UVB Device:
The hand-held device cost was estimated using manufacturer’s purchase price divided by 
an annuity factor (interest rate 3.5%, 5 years) to give an equivalent annual cost (EAC). 
EAC was divided by 12 months and multiplied by 9 to reflect the 9-month timeframe. The 
purchase price of personal protective equipment (goggles and glasses) were included at 
full cost since these are unlikely to be as durable as the devices. Costs of quality 
assurance process for the devices were included. Device repair and replacement costs 
were not included in the analysis faulty devices were replaced in the study: though in 
practice some might be repaired.
Time spent by investigators training participants on using the device was recorded and 
costed.
Topical Corticosteroid
Participants in the TCS intervention group were supplied with two 90g tubes of 
mometasone furoate 0.1% ointment (Elocon® 0.1% Ointment, Merck Sharp & Dohme, 
Hertford). TCS costs were was sourced from the Prescription Cost Analysis for 201711 
and had the National Average Discount Percentage of 7.37% 
(https://www.nhsbsa.nhs.uk/prescription-data/understanding-our-data/financial-
forecasting) deducted. The professional pharmacist fee of £1.29 was added, assuming 
that a single tube would be prescribed at any one time. Additional ointment requested by 
participants was recorded and costed. A
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Trial participants in all treatment groups were offered appointments with a dermatologist 
at 0, 3, 6, and 9 months, we assumed in the analysis that this would happen in routine 
care . These were costed even though they cancel each other out between treatment 
groups.
Side effects requiring medical attention from either treatment were recorded as one type 
of unscheduled contact.
Unit costs were identified from published sources, see Table 1, and valued in 
UK£Sterling 2017. Patient-reported estimates of out of pocket costs resulting from vitiligo 
were captured. 
Clinical outcome: Treatment success
The primary clinical outcome measure in the HI-LIGHT trial was participant-reported 
treatment success, measured at 9 months, using the Vitiligo Noticeability Scale (VNS)14. 
Treatment success, a binary outcome, was defined by whether the participant responded 
that their target vitiligo patch was “a lot less noticeable” or “no longer noticeable” in 
response to the question: "Compared to the start of the study, how noticeable is the 
vitiligo now?". Because no previous studies have compared the treatments or outcome 
used in this study, we used a single study-based estimate of effectiveness in the cost-
effectiveness analysis.
Quality of Life
Quality Adjusted Life Years (QALYs) were estimated in secondary analyses using utility 
scores obtained from the EQ-5D-5L instrument for participants aged 11+ years18, and the 
CHU-9D in the analysis focussed on children <18 years.15-17 For participants aged 5-6 
years old, the CHU-9D was completed by parental proxy. For all other ages these 
instruments were self-completed. We chose to use just one version of the EQ-5D-5L in 
the study for consistency. We chose the CHU-9D for the youngest participants because 
the EQ-5D-Y does not currently have a UK valuation set.  .
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Utility measurements were collected in clinic at baseline, 9,  and 21 months to reflect the 
likely timeframe for observing a clinically meaningful treatment response and in order to 
observe if any response found was sustained longer term. 
In the cost utility analysis, quality of life instrument responses were converted to utility 
scores using the EQ-5D-5L Crosswalk19 UK preference weights in line with current 
recommendations20, 21. The CHU-9D was valued using the UK value set15. Following this, 
the utility values were used to calculate quality adjusted life years (QALYs) generated 
over the trial treatment period of 9 months, using both linear interpolation and area under 
the curve analysis with  baseline adjustment24. 
Economic analysis
The economic primary analysis was performed on the full analysis set.  In line with the 
primary statistical analysis10, multiple imputation was used to account for missing primary 
outcome data at 9 months. Cost analyses employed multiple imputation with chained 
equations using MI impute in STATA generating 60 (m=60) datasets using predictive 
mean matching and separately by treatment allocation as reported by Faria et al23. Given 
the 9-month time horizon, costs and benefits were not discounted. 
Mean (SD) resource use and cost per participant was estimated for each randomised 
group. Mean difference (95% CI) in resource use and cost between arms (NB-UVB 
compared to TCS; and combination treatment compared with TCS) is presented. 
Costs and QALYs were adjusted for age and location of target patch as well as baseline 
utility using seemingly unrelated regression (SUR)24.
Non-parametric bootstrapping was used to determine sampling uncertainty surrounding 
the mean Incremental Cost Effectiveness Ratios (ICERs) by generating 10,000 estimates 
of incremental costs and benefits. These estimates were used to produce Cost-
Effectiveness Acceptability Curves to show the probability each intervention arm is cost 
effective at different values of willingness to pay. 
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Other than pre-planned secondary analysis based on the different utility instruments used 
(EQ-5D-5L and CHU-9D), no subgroup analyses were undertaken. The secondary 
outcome for the economic evaluation is quality-adjusted life years (QALYs) of participants 
over 9 months. Mean (SD) utility and mean (SD) QALYs per participant per randomised 
group is estimated, as is mean difference (95% CI) in QALYs between arms (NB-UVB to 
TCS; and combination treatment compared with TCS) adjusted for age and location of 
target patch. In secondary analyses, the reported economic analysis used a cost-
effectiveness threshold of £20,000 per QALY8.
All analyses were conducted in Stata MP4 version 15.
Sensitivity analyses were undertaken to explore key uncertainties including (i) comparing 
multiple imputation analysis to a complete case analysis, (ii) varying NB-UVB device 
costs (zero and double the price in the primary analysis), (iii) wider cost perspective 
including vitiligo out-of-pocket costs, (iv) limiting analysis to participants with good 
adherence (defined as greater than 75% adherence), and (v) extending the time horizon 
to 21 months to include the 12 months follow-up period.
It was expected that the majority of costs and benefits would be captured in the treatment 
period such that a priori it was not considered necessary to develop a decision-analytic 
model for a longer timeframe. This proved appropriate, as quality of life scores were 
similar between treatment arms at 21 months (see supplementary Table 6 in the clinical 
paper10). 
Results
Baseline characteristics of the participants included in the cost effectiveness analysis are 
described in Table 1 of Thomas et al (submitted)10. With imputation 517 participants (398 
adults, 119 children; 173 TCS, 169 NB-UVB, and 175 Combined treatment) were 
included.
Intervention costs
Mean number of devices, googles, glasses, drug costs, dermatology appointments, 
training and unscheduled visit/telephone by group (Table 2) and mean costs (Table 3) A
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are reported. The mean cost of the intervention per participant for TCS (standard care) 
was £583.42 (SD 29.59), £753.06 (SD 59.16) for NB-UVB, and £792.06 (SD 94.61) for 
combination treatment. Details of the time and cost of quality assurance processes are 
shown in Supplementary Table 1.  
Training time was a mean of 73.08 minutes for NB-UVB and 69.17 minutes for 
combination treatment, noting that all participants received both a device and ointment 
(dummy devices and placebo ointment were not costed). 
Wider resource use and costs 
Wider health care resource use (primary care, secondary care and medicines) for vitiligo 
beyond those required for the intervention were not significantly different between groups 
(Table 2). Vitiligo patients reported low NHS healthcare usage. Table 3 displays mean 
costs per participant by treatment group using available case data. The overall mean cost 
per participant for NB-UVB was £774.64 (SD 83.71) compared to £599.98 (SD 96.18) for 
TCS - an unadjusted mean difference in cost of £174.66 (95% CI 152.75 to 196.66). 
Combination treatment had overall mean costs per participant of £813.38 (SD 111.39); 
compared to TCS this gave an unadjusted mean difference of £213.40 (95% CI 188.33 to 
238.46) per participant. These figures suggest that the costs of the interventions were not 
offset by reductions in wider healthcare resource use related to vitiligo. 
Primary Economic Analysis
Cost effectiveness analysis of NB-UVB compared to TCS (standard care)
The adjusted incremental difference in cost was £173.44 (95% CI 150.55 to 196.32). The 
adjusted risk difference for NB-UVB compared to TCS was 5.20%, this equates to a 
number needed to treat (NNT) of 19; in other words, 19 participants would need to be 
treated for one of them to gain treatment success. The adjusted incremental cost was 
£3,335.74 per additional successful treatment (estimated by dividing the adjusted 
incremental difference in cost, £173.44, by the adjusted risk difference, 0.052).
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Figure 1a shows the probability that NB-UVB is cost-effective at different possible levels 
of willingness to pay for an additional treatment success; probability increases as 
willingness to pay increases. Figure 1a shows considerable uncertainty surrounding the 
decision as to whether NB-UVB, compared to TCS, represents value for money as there 
is always at least 40% probability of making the wrong decision if choosing to fund NV-
UVB alone below a threshold value of willingness to pay of £10,000 per additional 
treatment success.
Cost effectiveness analysis of combination treatment compared to TCS (standard 
care)
The adjusted incremental difference in cost was £211.46 (95% CI 188.10 to 234.81). The 
adjusted risk difference for combination treatment compared to TCS was 10.94%. This 
equates to a NNT of 9. The adjusted incremental cost was £1,932.35 per additional 
successful treatment.
Figure 1b shows the probability that combination treatment is cost-effective at different 
possible levels of willingness to pay for an additional treatment success and shows that 
combination treatment is likely to be cost effective if decision makers are willing to pay 
more than £3,000 per additional treatment success as the probability of making the 
wrong decision is less than 50%. 
Sensitivity analyses exploring key uncertainties in the economic evaluation are 
summarised in Supplementary Table 2. Limiting analysis to only adherent participants 
made the most difference to the incremental cost effectiveness ratio (£1,836.31 for 
combination treatment compared to TCS and £3,152.30 for NB-UVB compared to TCS), 
with those adherent to treatment being more likely to be cost effective to treat. 
Secondary Economic Analysis
248 (55%) trial participants reported having no problems on any of the five domains of 
the EQ-5D-5L at baseline, suggesting that over half of the sample started the study in A
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perfect health as defined by EQ-5D-5L. To put this value into perspective, in a general 
population sample from England the number of participants reporting no limitations on 
any dimension of the EQ-5D-5L was 43.87%25. Thus, the ceiling effect in this study can 
be considered large and of an order such as to limit the discriminatory power of the 
instrument for this patient population. Similar levels of ceiling effect were observed at 
subsequent follow-up. Similarly, for the CHU-9D 30% of participants aged under 18 years 
had no problems according to any of the nine dimensions on the CHU-9D at baseline. 
Anxiety and depression on the EQ-5D-5L and Worry, tiredness and sleeping on the CHU-
9D were the domains for which problems were reported most commonly. No floor effect 
was observed at any time point on either instrument. As these high ceiling ratios 
suggests these instruments are unlikely to be able to detect change, we report the mean 
utility estimates in supplementary Tables 3 and 4 and the cost utility analyses in 
supplementary Table 5. With this limitation in mind, both NB-UVB and combination 
treatment compared to TCS (standard care) had cost utility ratios within accepted 
thresholds (<£20,000 per QALY) for the sample aged 11 + years (NB-UVB was superior 
compared to TCS than combination treatment in contrast to the cost-effectiveness 
analysis). Neither treatment was cost-effective in the analyses of those participants 
aged<18 years but this may reflect the small sample size (n = 119).
Discussion
We present the first full economic evaluation of treatments for vitiligo using standard care 
TCS as the comparator. The additional cost of the combination treatment was not offset 
by NHS cost savings but did result in significant treatment success over the 9 month 
treatment period which could be gained if decision makers were willing to pay more than 
the adjusted incremental cost of £1,932.35 per additional successful treatment. NB-UVB 
was less costly than combination treatment but also less effective, such that the 
incremental cost per successful treatment was higher than for combination treatment, 
suggesting that the NHS would get better value for money from combination treatment 
than light therapy alone. There is currently no evidence to indicate how much a decision 
maker would be willing to pay for an additional treatment success as defined in this study. A
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Should the decision makers’ willingness to pay per additional treatment success be low 
then uncertainty surrounding the decision to fund combination treatment is high.
Treatment options are limited for vitiligo and existing treatments are used little in the NHS 
which may be due to treatments not being offered rather than absence of need.26
Cost effectiveness analysis was undertaken as the primary analysis because it enabled 
us to analyse all participants together, irrespective of age. We had a prior belief that 
generic utility instruments may not fully capture the health-related quality of life 
impairment of people living with vitiligo. This was supported by a high ceiling effect on the 
EQ-5D-5L and CHU-9D at baseline such that there was no capacity to measure any gain 
using these instruments for many participants. The cost utility analysis gave different 
results to the clinical and cost effectiveness results, in that NB-UVB appeared more cost 
effective than combination treatment, compared to TCS for those aged 11 and over. 
There was also a difference in results between the cost utility analyses undertaken by 
age, the new interventions were estimated as cost-effective in those aged 11 and over 
but not in those aged <18 years. This could reflect the different utility instrument used but 
more likely reflects the small sample size of the <18 years analysis and the fact that there 
was  a lot of uncertainty around the QALYs gained as the gain between groups was very 
close to zero in all comparisons. Therefore, more weight should be attached to the 
clinical effectiveness results and further work to explore the validity of the EQ-5D-5L and 
CHU-9D in this patient group is warranted, given the high ceiling effect observed in this 
study. It may be that a disease specific utility instrument needs to be developed for 
vitiligo. 
Sensitivity analyses suggested that a wider perspective, cost of the NB-UVB light device, 
and method of dealing with missing data did not change the conclusions reached. 
Incremental cost per treatment success was lowest for those with greatest adherence. 
New treatments such as Janus Kinase (JAK) inhibitors are being developed for vitiligo 
and are likely to be costly. The relatively low cost of the interventions assessed in this 
trial may make them affordable when resources are limited. The trial has yielded useful 
cost-effectiveness data which can be used for future comparisons with novel treatments.A
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A strength of the study was that the HI-Light trial was a large, pragmatic trial of home 
interventions for people with active, limited vitiligo that controlled for common causes of 
bias. Retention throughout the trial was challenging, and the treatments placed 
considerable time burden on participants. Because less than 50% responded to 
secondary outcomes at 21 months, a longer term economic evaluation to 21 months was 
not undertaken, which is a limitation of the present study. However, given treatment 
effects beyond the 9-month period were not sustained one can assume that the cost-
effectiveness of the interventions would likely decline over time if treatments were not 
continued.
Conclusion
Combination treatment, compared to TCS alone, has a lower incremental cost per 
successful treatment than NB-UVB but whether this is considered cost-effective will 
depend on how much healthcare decision makers are willing to pay to achieve a 
successful treatment. The fact that vitiligo has few treatment options available, and the 
likely high cost of newer treatments being developed, may influence these decisions. 
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Table 1 Unit Costs Table (UK£ sterling, 2017) 
Resource Item Unit Cost 
(£2017) 
Source (notes) 
Intervention resources 
Annuity factor  4.515 based on 
r = 3.5% and n = 
5 
Drummond et al.4 
Purchase price 149.00 Dermfix Ltd website 
Annuitised 9-month purchase pricea 24.75 (Purchase price divided by annuity factor to give 
equivalent annual cost (EAC). EAC divided by 12 
months and multiplied by 9.) 
Annuitised 9-month quality assurance (£17.83 
multiplied by annuity factor)  
2.96  
 
Quality assurance: Medical Physics, Nottingham 
University Hospitals 
Glasses (per set) 15.00 Dermfix Ltd website 
Goggles (per set) 7.00 Dermfix Ltd website 
TCS (per 90g tube of mometasone furoate 0.1%) 12.13 Health and Social Care Information Centre Prescription 
Cost Analysis11 
Investigator face to face and telephone support (per 
minute, assumed band 7 £54 per hour) 
0.90 PSSRU 201712 
Dermatologist Face to face first appointment 159.00 NHS Schedule of Reference Costs13 A
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consultant-led 
Dermatologist Face to face follow-up appointment 
consultant-led 
129.00 NHS Schedule of Reference Costs13 
Dermatologist telephone appointment consultant-led 100.00 NHS Schedule of Reference Costs13 
Training time (per minute, assumed band 7 £54 per 
hour) 
0.90 PSSRU 201712 
Primary Care resources (per visit) 
GP  37.00  PSSRU 201712 
Practice Nurse  10.85  PSSRU 201712 
Pharmacist (assumed to be a community pharmacist)  11.11  PSSRU 201712 
Hospital Doctor  53.33  PSSRU 201712 
Hospital Nurse  15.00 PSSRU 201712 
Therapist  27.00  PSSRU 201712 
Other (reported by participants) Range from 
15.00 to 86.00 
 PSSRU 201712 and NHS Schedule of Reference 
Costs13 
Other Resources 
Medication (Various, NIC per item less NADP plus 
professional fee) 
Range from 3.37 
to 36.92 
 PCA 201711 
Participant and family out of pocket costs Various Estimates reported by participants 
Acronyms:  NADP = National Average Discount Percentage; NIC = Net Ingredient Costs; TCS = Topical Corticosteroids.  A
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Table 2 Mean (Standard Deviation) resource use according to intervention arm over the 9-month treatment phase for all 
participants (based on available data) 
 TCS  
(Standard Care) 
(n=173) 
NB-UVB (n=169) Mean difference  
(NB-UVB minus 
TCS) 
Combination 
treatment (n=175) 
Mean 
difference  
(Combination 
minus TCS) 
 Mean Std dev (n) Mean Std dev (n) (95% CI) Mean Std dev (n) (95% CI) 
Intervention     
NB-UVB 
intervention* 
0.00 0.00 (173) 1.08  0.30 (169) 1.083 
(1.04 to 1.13) 
1.07 0.30 (175) 1.07 
(1.03 to 1.12) 
Glasses^ 0.00 0.00 (173) 1.41 0.58 (169) 1.41 
(1.33 to 1.50) 
1.50 0.56 (175) 1.50 
(1.41 to 1.58) 
Goggles^ 0.00 0.00 (173) 0.46 0.60 (169) 0.46 
(0.37 to 0.54) 
0.40  0.56 (175)  0.40 
(0.32 to 0.48) 
TCS 2.15 0.55 (173) 0.00 0.00 (169) -2.15 
(-2.23 to -2.07) 
2.12   0.49 (175) -0.03   
(-0.14 to 0.08) 
Training time 
(mins) 
0.00 0.00 (173) 73.08 40.47 (169) 73.08  
(67.03 to 79.13) 
69.17 34.51  (175) 69.17 
(64.01 to 74.33) 
Dermatologist 
time (clinic + 
4.00 0.00 (173) 4.00 0.00 (169) 0.00 
(0.00 to 0.00) 
4.00 0.00 (175) 4.00  
(4.00 to 4.00) A
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telephone) 
Nurse time 
(clinic + 
telephone) 
0.00 0.00 (173) 2.00 0.00 (169) 2.00 
(2.00 to 2.00) 
2.00 0.00 (175) 2.00  
(2.00 to 2.00) 
Unscheduled 
clinic with 
Nurse 
0.01 0.11 (173) 0.03 0.20 (169) 0.02   
(-0.02 to 0.05) 
0.13 0.51 (175) 0.12 
(0.04 to 0.20) 
Unscheduled 
telephone 
with Nurse 
0.39 0.87 (173) 0.46  0.95 (169) 0.07   
(-0.13 to 0.26) 
0.66 1.29 (175) 0.28  
(0.04 to 0.51) 
Unscheduled 
clinic with 
dermatologist 
0.02  0.13 (173) 0.04  0.20 (169) 0.02 
(-0.01 to 0.06) 
0.10 0.43 (175) 0.09 
(0.02 to 0.15) 
Unscheduled 
telephone 
with 
dermatologist 
0.02 0.17 (173) 0.03 0.20 (169) 0.01 
(-0.03 to 0.05) 
0.05 0.27 (175) 0.03  
(-0.01 to 0.08) 
Primary Care and Community     
Number 0.12 0.44 (136) 0.17 0.64 (132) 0.06  
(-0.07 to 0.19) 
0.12 0.55 (142) .002  
(-0.12 to 0.12) 
Secondary Care     A
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Number 0.48  4.47 (136) 0.20 0.61 (132)  -0.28 
(-1.05 to 0.49) 
0.20 0.63 (142)  -0.28  
(-1.03 to 0.46) 
Other     
Medication 0.12 0.50 (138) 0.08 0.35 (133) -0.04 
(-0.14 to 0.06) 
0.09  0.34 (141) -0.03   
(-0.13 to 0.07) 
Out of pocket 
purchases 
0.40 1.44 (141) 0.28 0.88 (137) -0.12 
(-0.40 to 0.16) 
0.31   1.27 (144) -0.09   
(-0.41 to 0.23) 
* Includes number of NB-UVB devices only.^ participants could choose to have more than one set, for instance if they needed a 
parent or partner to help them deliver the treatment.  
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Table 3 Mean (Standard Deviation) costs and outcomes according to intervention arm over 9-month treatment phase 
(UK£Sterling, 2017) for all participants (based on available data) 
 TCS (Standard 
Care)  (n=173) 
NB-UVB (n=169) Mean difference 
(NB-UVB minus 
TCS)  
Combination 
treatment (n=175) 
Mean difference  
(Combination 
minus TCS) 
 Mean Std dev 
(n) 
Mean Std dev (n) (95% CI) Mean Std dev (n) (95% CI) 
Intervention 
NB-UVB 
Device 
0.00  0.00 (173) 24.75 0.00 (169) 24.75 
(24.75 to 24.75) 
24.75 0.00 (175) 24.75 
(24.75 to 24.75) 
Quality 
assurance for 
device 
0.00  0.00 (173) 2.96  0.00 (169) 2.96 
(2.96 to 2.96) 
2.96 
 
0.00 (175) 2.96 
(2.96 to 2.96) 
Glasses 0.00  0.00 (173) 21.21 8.74 (169) 21.21 
(19.91 to 22.52) 
22.46  8.34 (175) 22.46 (21.21 to 
23.70) 
Goggles 0.00  0.00 (173) 3.19 4.18 (169) 3.19 
(2.56 to 3.81) 
2.80   3.90 (175) 2.80  
(2.22 to 3.38) 
TCS 26.08 6.67 (173) 0.00 0.00 (169) -26.08 
(-27.09 to -25.07) 
25.71 5.99 (175) -0.37 
(-1.70 to 0.97) 
Training time 0.00  0.00 (173) 65.77 36.42 (169) 65.77 
(60.32 to 71.22) 
62.25 31.06 (175) 62.25 
(57.61 to 66.90) A
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Dermatologist 
(clinic + 
telephone) 
546.00 0.00 (173) 546.00  0.00 (169) 0.00 
(0.00 to 0.00) 
546.00 0.00 (175) 546  
(546.00 to 546.00) 
Nurse (clinic 
+ telephone) 
0.00  0.00 (173) 72.00 0.00 (169) 72.00  
(72.00 to 72.00) 
72.00 0.00 (175) 72.00 
(72.00 to 72.00) 
Unscheduled 
clinic with 
Nurse 
0.21  1.93 (173) 0.53 3.64 (169) 0.32 
(-0.29 to 0.94) 
2.41 9.53 (175)   2.20 
(0.75 to 3.66) 
Unscheduled 
telephone 
with Nurse 
7.16  16.30 
(173) 
8.34 17.53 (169) 1.19 
(-2.41 to4.79) 
12.30 23.92 (175) 5.14 
(0.82 to 9.46) 
Unscheduled 
clinic with 
dermatologist 
2.24 16.89 
(173) 
5.34 25.78 (169)  3.11 
(-1.52 to 7.73) 
13.27 55.45 (175) 11.03 
(2.37 to 19.70) 
Unscheduled 
telephone 
with 
dermatologist 
1.73 16.96 
(173) 
2.96 20.20 (169) 1.22   
(-2.74 to 5.19) 
5.14   26.84 (175) 3.41   
(-1.33 to 8.15) 
Total cost of 
intervention 
583.42 29.59 
(173) 
753.06 59.16 (169) 169.64 
(159.73 to 
179.56) 
792.06   94.61 (175) 208.64 
(193.82 to 223.46) 
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Primary Care and Community 
Cost 3.90 15.21 
(136) 
5.90  22.20 (132) 2.00   
(-2.56 to 6.57) 
2.84 14.09 (142) -1.06   
(-4.52 to 2.40) 
Secondary Care 
Cost 11.05 77.14 
(136) 
9.30 30.05 (132) -1.74 
(-15.90 to 12.42) 
8.52 26.87 (142) -2.53 
(-16.05 to 11.00) 
Other 
Medication 2.48 10.52 
(138) 
1.49 7.06 (133) -0.99 
(-3.14 to 1.16) 
1.20  6.09 (140) -1.28   
(-3.30 to 0.75) 
Total mean 
cost per 
participant 
599.98   96.18 
(132) 
774.64 83.71 (131) 174.66 
(152.75 to 
196.56) 
813.38 111.39 
(136)   
213.40 
(188.33 to 238.46) 
Out of pocket 
costs 
14.44 96.78 
(141) 
4.94 20.09 (137)  -9.49  
(-26.11 to 7.12) 
6.62 28.45 (144) -7.81 
(-24.37 to 8.75) 
Primary outcome    
VNS*  20/119 
(16.81%) 
 27/123 
(21.95%) 
 7 (5.14%)^ 34/128 
(26.56%) 
 14 (9.75%) 
*The number (the percentage) of participants who reported a treatment success (VNS) (a lot less noticeable or no longer 
noticeable) at 9 months divided by the number of participants with primary outcome recorded at 9 months. ^ Between group 
difference is number of participants experiencing a treatment success (between group risk difference %). 
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Figure 1a: Cost effectiveness Acceptability curve for NB-UVB versus TCS                   Figure 1b: Cost effectiveness Acceptability curve for NB-UVB versus TCS 
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